Deep Learning Image Reconstruction for Gemstone Spectral Imaging
GE Medical Systems, LLC • Radiology • 12/10/2020
Device Purpose
The Deep Learning Image Reconstruction for Gemstone Spectral Imaging (DLIR-GSI) system utilizes a specialized Convolutional Neural Network to reconstruct high-quality cross-sectional images from dual-energy CT data acquired via Gemstone Spectral Imaging. This technology aims to enhance diagnostic capabilities by improving image quality metrics such as noise reduction, contrast, and material decomposition accuracy compared to previous reconstruction methods like ASiR-V, supporting diverse clinical applications including whole body, vascular, and head imaging.
Summary
Deep Learning Image Reconstruction for Gemstone Spectral Imaging (DLIR-GSI) is an advanced computed tomography (CT) image reconstruction system designed to process dual-energy X-ray transmission data. Its core methodology involves a dedicated Convolutional Neural Network (CNN) specifically trained with dual-energy CT images acquired using Gemstone Spectral Imaging (GSI) technology. This deep learning approach aims to produce high-quality cross-sectional images, including monochromatic (MC), material decomposition (MD) of substances like iodine, water, and calcium, and virtual unenhanced (VUE) images. The science behind DLIR-GSI lies in its ability to model complex noise characteristics and image features, offering an alternative to traditional reconstruction methods like Filtered Back Projection (FBP) and iterative reconstructions like ASiR-V, with selectable strengths (Low, Medium, High) to suit user preference and clinical needs. DLIR-GSI is intended for whole-body, vascular, and contrast-enhanced head CT applications across all age groups. Performance evaluations, including non-clinical bench testing and clinical reader studies, compared DLIR-GSI to the ASiR-V reconstruction technique. These studies demonstrated that DLIR-GSI provides equivalent or superior imaging performance in areas such as low contrast detectability, image noise reduction, contrast-to-noise ratio, high-contrast spatial resolution, CT number accuracy, material decomposition quantification accuracy, and metal artifact reduction. Clinical evaluations involving radiologists confirmed that DLIR-GSI produces diagnostic quality images, with a preferred noise texture compared to ASiR-V, even in clinically challenging cases involving small, low-contrast objects. The system is compatible with GE's Revolution CT family and produces DICOM-compatible "TrueFidelityTM CT Images".
AI Regulatory Concerns
Powered by
Jev reads the full FDA letter and returns calibrated concern probabilities per regulatory category. These are AI estimates, not regulatory advice.
Keywords
Device Metadata
Relevant Clinical Questions
- Q1. How does the performance of DLIR-GSI's material decomposition (e.g., iodine quantification, virtual unenhanced images) compare quantitatively to traditional dual-energy GSI post-processing methods across different anatomical regions and patient populations?; What is the impact of the three user-selectable strengths (Low, Medium, High) of DLIR-GSI on specific diagnostic tasks, and are there established guidelines for selecting the optimal strength for different clinical indications or patient characteristics?; Beyond the stated improvements in image noise and low-contrast detectability, what is the computational time difference for DLIR-GSI reconstruction compared to ASiR-V and standard FBP, and how does this impact clinical workflow for high-throughput departments?; Given that the CNN was trained specifically on the Revolution CT family, how robust is the DLIR-GSI algorithm to variations in acquisition parameters (e.g., kVp settings, mAs, pitch) and patient-specific factors (e.g., body habitus, presence of implants) not extensively covered in the training dataset?; What are the specific characteristics of the 'preferred noise texture' achieved by DLIR-GSI, and how does this texture influence radiologists' diagnostic confidence and detection of subtle pathologies compared to the texture produced by ASiR-V?
Risk Classification
ESL AnalysisFDA Class II via 510(k) pathway; IEC 62304 Class B (software safety classification); Authorized before §524B enforcement
Learn how Parasoft automates IEC 62304 compliance testing →Cybersecurity Evidence
Powered by SBOMator™Based on AI-generated device summaries, not the full FDA submission. Items not detected here may still be present in the complete submission package.
Supply Chain BOM Evidence
Based on the CycloneDX / OWASP ECMA-424 xBOM ecosystem. Detection is from the AI-generated summary.
Analysis:
• Analysis is based on the AI-generated device summary, not the full FDA submission package. Click "Analyze Full FDA PDF" below to scan the actual submission document.
• Evidence of ML-BOM, SaaSBOM detected in AI-generated device summary.
• This device was authorized before §524B took effect. Cybersecurity evidence requirements were less prescriptive at the time.
• Postmarket cybersecurity monitoring plan not clearly documented in AI-generated device summary.
• Not detected in AI-generated device summary: SBOM, HBOM, CBOM, VDR/VEX, OBOM. These may be present in the full FDA submission.
Preparing a similar submission?
ESL takes complete ownership of your software evidence work - SBOM & CVE remediation with SBOMator™, static analysis & unit testing with Parasoft, traceability, and full IEC 62304 lifecycle support.
Assess Your Readiness →Or contact ESL directly